Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma

Cisplatin-based chemotherapy is the standard of care for patients with muscle invasive urothelial carcinoma. Pathologic downstaging to pT0/pTis after neoadjuvant cisplatin-based chemotherapy is associated with improved survival, although molecular determinants of cisplatin response are incompletely...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer Discov
मुख्य लेखकों: Van Allen, Eliezer M., Mouw, Kent W., Kim, Philip, Iyer, Gopa, Wagle, Nikhil, Al-Ahmadie, Hikmat, Zhu, Cong, Ostrovnaya, Irina, Kryukov, Gregory V., O’Connor, Kevin W, Sfakianos, John, Garcia-Grossman, Ilana, Kim, Jaegil, Guancial, Elizabeth A., Bambury, Richard, Bahl, Samira, Gupta, Namrata, Farlow, Deborah, Qu, Angela, Signoretti, Sabina, Barletta, Justine A., Reuter, Victor, Boehm, Jesse, Lawrence, Michael, Getz, Gad, Kantoff, Philip, Bochner, Bernard H., Choueiri, Toni K., Bajorin, Dean F., Solit, David B., Gabriel, Stacey, D’Andrea, Alan, Garraway, Levi A., Rosenberg, Jonathan E.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2014
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4238969/
https://ncbi.nlm.nih.gov/pubmed/25096233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-14-0623
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन